Skip to main content

Table 3 Comparison of survived versus deceased patients with metformin-associated lactic acidosis

From: Outcome of severe lactic acidosis associated with metformin accumulation

  All patients with MALA (n= 10) Survived (n= 5) Deceased (n= 5)
Age, years 66 ± 9 64 ± 5 69 ± 11
Male gender 4 (40%) 3 (60%) 1 (20%)
SAPS II 88 ± 23 73 ± 25 103 ± 7
SOFA score 14.3 ± 1.4 13.8 ± 1.5 14.8 ± 1.3
   Respiratory 2.7 ± 0.9 2.4 ± 1.1 3.0 ± 0.7
   Renal 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0
   Hepatic 0.3 ± 0.7 0.4 ± 0.9 0.2 ± 0.4
   Cardiovascular 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0
   Hematologic 0.5 ± 0.8 0.4 ± 0.9 0.6 ± 0.9
   Neurologic 2.8 ± 1.5 2.6 ± 1.3 3.0 ± 1.7
Lactate, mmol/L 18.7 ± 5.3 17.7 ± 5.3 19.8 ± 5.7
pH 6.75 ± 0.13 6.72 ± 0.17 6.77 ± 0.07
Prothrombin activity, % 69.1 ± 27.7a 78.0 ± 24.6 58.0 ± 30.7a
Serum metformin, mg/L 55 ± 13 52 ± 7 58 ± 19
  1. Values other than 'Male gender', which is presented as number (percentage), are presented as mean ± standard deviation. aOne patient was omitted with 11% prothrombin activity due to cumarin therapy. MALA, metformin-associated lactic acidosis; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment.